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Abstract 
Theranostics, the combination of diagnosis and therapy, has long held promise as a means to achieving per-
sonalised precision cancer treatments. However, despite its potential, theranostics has yet to realise significant 
clinical translation, largely due the complexity and overriding toxicity concerns of existing theranostic nano-
particle strategies. Here, we present an alternative nanoparticle-free theranostic approach based on simultane-
ous Raman spectroscopy and photodynamic therapy (PDT) in an integrated clinical platform for cancer 
theranostics. We detail the compatibility of Raman spectroscopy and PDT for cancer theranostics, whereby 
Raman spectroscopic diagnosis can be performed on PDT photosensitiser-positive cells and tissues without 
inadvertent photosensitiser activation/photobleaching or impaired diagnostic capacity. We further demonstrate 
that our theranostic platform enables in vivo tumour diagnosis, treatment, and post-treatment molecular moni-
toring in real-time. This system thus achieves effective theranostic performance, providing a promising new 
avenue towards the clinical realisation of theranostics.  
 
Introduction 
A theranostic approach to cancer treatment, whereby 
therapeutic and diagnostic modalities are integrated 
into a single system, offers the potential for patient- 
or tumour-tailored therapies to improve clinical out-
comes1. Through the combination of an appropriate 
diagnostic modality and a suitable therapy, clinicians 
could modify treatment protocols based on real-time 
diagnostic feedback, thereby tuning therapies to the 
patient or lesion under examination. Successful 
theranostic cancer management, however, requires 
the careful selection of compatible cancer diagnosis 
and treatment modalities and their effective combina-
tion into a single system for clinical use2,3. This, un-
derstandably, presents a formidable challenge.  
To meet this challenge, existing theranostic strategies 
have primarily relied on the use of multifunctional 
(typically inorganic) nanoparticles for the conjuga-
tion, entrapment, or intrinsic demonstration of diag-
nostic and therapeutic agents2,4–6. Theranostic nano-
particle systems have been developed to enable MRI, 
CT, PET, and fluorescence imaging, in addition to 
chemotherapeutic compound delivery, providing a 
large library of potential diagnostic/therapeutic com-
binations7,8. Numerous studies have demonstrated 
theranostic constructs based on nanoparticle systems 
including gold nanoparticles4,9, carbon nanotubes10, 
quantum dots11,12, and upconversion nanoparti-
cles13,14. In these systems, optical modalities such as 
fluorescence imaging and Raman spectroscopy are 
regularly combined with phototherapies such as pho-
todynamic therapy (PDT) and/or photothermal thera-
py (PTT) due to the inherent complementarity that 
exists between these modalities7,15,16.  
Despite exciting developments, whereby single na-
noparticle systems perform as both diagnostic and 
therapeutic constructs, there remain significant con-
cerns that have thus far stymied clinical translation 
efforts3,17. Chief amongst these are ongoing safety 
concerns, namely due to the non-biodegradability 
and subsequent bioaccumulation of many nanoparti-
cle systems, as well as toxicities they may display18–
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21. Indeed, the complex synthesis required to intro-
duce multifunctionality into many such nanoparticle 
systems not only increases production costs and 
regulatory hurdles, but makes pharmacokinetic and 
pharmacodynamic studies more difficult, due to 
complex interactions that may exist between multi-
component structures and any encapsulated materi-
als22. Further compounding these issues is the inher-
ent trade-off that often exists between diagnostic and 
therapeutic modalities in terms of desired dosages 
and clearance rates23,24. While optimal diagnostic 
performance often requires minimal contrast agent 
with rapid clearance, therapeutics typically necessi-
tates maximal tolerated dosages for as long as possi-
ble to achieve high response3,22.  
Here, we demonstrate a theranostic approach to can-
cer treatment that avoids the need for complex inor-
ganic nanoparticles altogether. We employ a custom-
built, multimodal fibreoptic probe to combine Raman 
spectroscopy for cancer diagnosis with PDT for opti-
cal theranostics. Raman spectroscopy is an optical 
diagnostic modality capable of identifying subtle 
biochemical differences between tissues through the 
application laser light and subsequent collection of 
inelastically scattered light from tissue25,26. The re-
sulting biochemical spectral fingerprint has enabled 
real-time in vivo diagnoses of gastrointestinal can-
cers27–29, skin cancer30, breast cancer31, and cervical 
cancers32,33 with sensitivities and specificities of be-
tween 85% and 95%. Importantly, this diagnostic 
performance is achieved without the need for con-
trast agents such as nanoparticle systems, with diag-
nostic readouts based solely on the underlying bio-
chemistry of the tissues. Similarly, PDT is an optical 
therapeutic modality that combines light, oxygen, 
and a photosensitiser to provide spatially and tempo-
rally controlled tumour destruction34,35. Following 
local or systemic administration, photosensitiser acti-
vation by light of a specific wavelength produces a 
photochemical reaction that generates reactive oxy-
gen species resulting in controlled tumour destruction 
directly and indirectly36,37. Crucially, PDT photosen-
sitisers are small molecular compounds with existing 
clinical approvals, and have to date been applied for 
the treatment of skin cancers, oesophageal cancer, 
and head and neck cancer, among others38–41.   
Here we show, through the choice of an appropriate 
Raman spectroscopy excitation wavelength and the 
careful selection of PDT photosensitisers, it is possi-
ble to achieve effective cancer theranostics. Through 
extensive in vitro characterisation, we identify suita-
ble Raman spectroscopy and PDT parameters to-
wards clinical implementation of this approach. Fi-
nally, we demonstrate the feasibility of our 
theranostic approach using a custom-built, multi-
modal fibreoptic platform for the diagnosis, treat-
ment, and post-treatment molecular monitoring of 
colorectal xenograft tumours in an in vivo mouse 
model. Together, our results highlight a potential 
strategy for the clinical translation of theranostic 
cancer management concepts. 
 
Results 
Integrated Fibreoptic Raman Spectroscopy and 
Photodynamic Therapy 
We have developed a fibreoptic theranostic platform, 
capable of the simultaneous delivery of up to three 
laser light sources (Figure 1a). This theranostic plat-
form encompasses a fibreoptic probe (2 mm probe tip 
diameter) consisting of a central optical fibre for 
Raman spectroscopic excitation. Surrounding the 
central optical fibre are seven optical fibres, one for 
PDT excitation, one for alternate PDT excitation (at a 
third wavelength), and five for the collection of Ra-
man spectroscopic signal. Incorporated into the tip of 
this multimodal fibreoptic probe are distal optical 
components including shortpass filters, notch filters, 
and a focusing lens to maximise the efficient collec-
tion of Raman scattered light and the colocalised 
delivery of Raman and PDT laser light for contact or 
short distance applications. Figure 1b illustrates an 
example workflow using our developed theranostic 
platform for the diagnosis, treatment, and post-
treatment molecular monitoring of a cancerous le-
sion. Here, when used in conjunction with a suitable 
PDT photosensitiser, our multimodal probe enables 
theranostic operation to realise the goal of patient- or 
lesion-specific diagnosis at the molecular level, 
treatment, and importantly, post-treatment monitor-
ing of the tumour response to PDT via biomolecular 
fingerprinting. 
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Figure 1 | Multimodal Fibreoptic Probe for Nanoparticle-Free Optical Theranostics and Envisaged Surgical Workflow. 
(a) Schematic of clinical system comprising a multimodal optical probe, a spectrograph, laser sources for Raman spec-
troscopy and photodynamic therapy, and a computer with associated system control software; (inset, left) Excitation-
emission diagram demonstrating wavelength separation of diagnostic (Raman spectroscopy) and therapeutic (PDT) 
modalities. (b) Envisaged surgical workflow: (i), Raman spectroscopic identification of cancerous lesions; (ii) Photosensi-
tiser administration resulting in preferential photosensitiser uptake in diseased tissues with no impact on Raman spec-
troscopic diagnostic capabilities; (iii) Activation of photosensitisers in target lesions through illumination with PDT laser; 
(iv) Post-treatment monitoring of treated areas demonstrating destruction of cancerous lesions. 
 
Photosensitiser Selection and Characterisation 
We first examined three clinically employed photo-
sensitisers with excitation and emission profiles ex-
pected to be compatible with the 785 nm laser used 
for in vivo Raman spectroscopic diagnostics (Sup-
plementary Figure 1). 5-aminolevulinic acid (5-ALA) 
is a prodrug to the photosensitiser protoporphyrin IX 
(PPIX), both of which occur naturally at low concen-
trations within almost all human cells, with clinical 
approval for PDT of actinic keratosis, basal cell car-
cinoma, Bowen’s disease, and bladder cancer42–44. 
PPIX is excited at 633 nm for PDT, with fluores-
cence emission between 600 nm and 700 nm (Sup-
plementary Figure 1a, d). The second, verteporfin is 
a clinically-approved photosensitiser with an excita-
tion peak at 690 nm and fluorescence emission be-
tween 600 nm and 800 nm (Supplementary Figure 
1b, e)45,46. Though originally developed for cancer 
applications, verteporfin is most commonly applied 
to the treatment of choroidal neovascularisation47,48. 
The third photosensitiser, temoporfin, is activated at 
652 nm with fluorescence emission between 630 nm 
and 750 nm (Supplementary Figure 1c, f)49,50. Temo-
porfin is clinically approved in Europe for the treat-
ment of squamous cell carcinomas of the head and 
neck38.  
Each of these photosensitisers was selected as their 
clinical excitation wavelengths are far from the 785 
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nm wavelength used for Raman spectroscopic excita-
tion, and their fluorescence emissions fall well below 
the wavelength range from Raman spectroscopic 
signal collection. As expected, excitation of each of 
these photosensitisers at 785 nm produced almost no 
detectable fluorescence signal (less than 0.2% of the 
peak fluorescence signal upon photosensitiser excita-
tion at 405 nm), indicating their potential compatibil-
ity with Raman spectroscopy (Supplementary Figure 
1g-i). As a further initial screening of these photo-
sensitisers, we investigated the background fluores-
cence they generate in Raman spectra when meas-
ured in solution using our multimodal fibreoptic 
probe (Supplementary Figure 2). In each case, at 
photosensitiser concentrations in solution of up to 
1000 ng/mL (1.78 µM PPIX, 1.47 µM temoporfin, 
1.39 µM verteporfin), no significant detectable in-
crease in fluorescence background due to the photo-
sensitiser was observed, indicating Raman spectro-
scopic diagnostics could likely be performed on tis-
sues with comparably high photosensitiser concentra-
tions. Indeed, work quantifying PPIX levels present 
in high-grade gliomas (which demonstrate very high 
PPIX accumulation) following 5-ALA application 
for fluorescence-guided surgery has previously indi-
cated a mean concentration of 5.8 µM51. We antici-
pate that with the added scattering effects of tissues, 
Raman spectroscopy of lesions with similar PPIX 
concentrations would be possible. 
Compatibility of Raman Spectroscopy and Photo-
dynamic Therapy In Vitro 
The successful combination of Raman spectroscopy 
and PDT for cancer theranostics relies on a lack of 
interference between the two modalities. Firstly, it is 
essential to demonstrate that the laser used for Ra-
man spectroscopy does not cause undesired prema-
ture activation of the photosensitisers employed for 
PDT. Inadvertent activation of photosensitisers could 
result in damage to healthy tissue and/or photo-
bleaching of the photosensitiser, limiting the efficacy 
of PDT treatment on diseased tissues. Secondly, the 
intrinsic fluorescence of the photosensitisers must not 
impact or occlude the Raman spectral information 
obtained. Raman scattering is inherently weak and is 
therefore easily masked by stronger fluorescence 
signals52. In order to effectively perform molecular 
Raman diagnostics, a clear, strong signal is required 
for spectral discrimination of different pathologies. 
To assess the compatibility of these two modalities, 
we first employed cell viability assays to investigate 
whether the 785 nm laser wavelength used for in vivo 
Raman spectroscopy activates any of the photosensi-
tisers when tested at clinically relevant concentra-
tions (Figure 2a-c and Supplementary Figure 3a-f).  
CCK-8 cell viability assays were performed on three 
different cell lines, A549 lung carcinoma cells, 
MDA-MB-231 breast adenocarcinoma cells, and 
MDA-MB-436 breast adenocarcinoma cells. In each 
case, illumination at the photosensitiser-specific 
wavelength resulted in photosensitiser dose-
dependent cell death, while illumination at 785 nm 
did not affect cell viability relative to no illumination 
controls. These data thus indicate that Raman spec-
troscopy could be performed on photosensitiser-
containing tissues in vivo without causing photosen-
sitiser activation.  
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Figure 2 | Compatibility of Raman Spectroscopy and Photodynamic Therapy In Vitro. (a-c) CCK-8 cell viability assay of 
A549 cells incubated with (a) 5-ALA (PPIX prodrug), (b) Verteporfin, or (c) Temoporfin, at varying concentrations and 
illuminated with either the photosensitiser-specific LED array (633 nm, 690 nm, or 660 nm), the 785 nm LED array, or 
not illuminated (mean ± S.D., N = 3, n = 6) (Multiple comparisons t-test, Bonferroni post hoc correction, * P < 0.05, ** P 
< 0.01, *** P < 0.001). (d-f) Raman spectral acquisitions (10 s integration time) of cells in the presence of different pho-
tosensitisers (phenol red-free DMEM (Control), 5-ALA (10000 µM), Verteporfin (100 ng/mL), or Temoporfin (10 ng/mL)) 
(N = 10, n = 5). (d) A549 cells, (e) MDA-MB-231 cells, (f) MDA-MB-436 cells. (g) Partial Least Squares – Discriminant 
Analysis (PLS-DA) of Raman spectra from three different cell lines (A549, MDA-MB-231, and MDA-MB-436) incubated 
with one of the three photosensitisers or no photosensitiser, performed across cell line (N = 40, n = 5 for each cell line) 
with classification accuracies of A549: 98.3%, MDA-MB-231: 100.0%, and MDA-MB-436: 98.3%.  (h-k) Confocal fluores-
cence images of photosensitiser positive A549 cells (h) Control, (i) (5-ALA induced) PPIX, (j) Verteporfin, (k) Temoporfin 
(scale bars 10 μm). 
 
Next, to determine whether photosensitiser fluores-
cence impacts the Raman spectral information ob-
tained, we collected Raman spectra using a confocal 
Raman microspectroscopy system at 785 nm from 
each of the three cell lines without photosensitiser 
and with each photosensitiser at the maximal dose 
tested for the cell viability assays (Figure 2d-f). For 
each cell type, the Raman spectra appeared grossly 
similar, with no substantial occlusion of the Raman 
spectral signal as would be expected for compounds 
with fluorescence emission in the Raman spectral 
range. Raman difference spectra between the photo-
sensitiser positive cells and the control cells demon-
strated only subtle spectral differences, potentially 
due to increased background noise induced by photo-
sensitiser fluorescence (Supplementary Figure 4). 
Indeed, the raw Raman spectra for each cell line did 
show some changes in background fluorescence, 
with particularly notable increases in background 
fluorescence for MDA-MB-231 Temoporfin and 
Verteporfin cells (Supplementary Figure 5). Howev-
er, in each case, the overall shape of the Raman spec-
trum and the key spectral peaks were maintained. 
This was further confirmed through assessment of 
the mean spectral coefficient of variation and the 
signal-to-noise ratio (SNR) (calculated as the peak 
intensity at 1650 cm-1 divided by the mean standard 
deviation between 1780-1820 cm-1) for each spec-
trum. These indicated generally consistent values 
across the processed Raman spectra, with increases 
in the mean spectral coefficient of variation and de-
creases in the SNR observed in the raw Raman spec-
tra of the Temoporfin and Verteporfin cells (Supple-
mentary Figure 6).  
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Partial least-squares – discriminant analysis (PLS-
DA) provided further demonstration that the fluores-
cence of the photosensitisers investigated did not 
impact the Raman spectral information acquired 
(Figure 2g and Supplementary Figure 7). This analy-
sis, performed using a Venetian blinds cross-
validation, successfully classified cell spectra accord-
ing to their respective cell phenotype with accuracies 
of greater than 98% (A549: 98.3%, MDA-MB-231: 
100.0%, MDA-MB-436: 98.3%) irrespective of the 
presence of a photosensitiser within the cell. This 
provided further evidence that the processing per-
formed on the raw Raman signal effectively account-
ed for minor spectral variations due to the presence 
of photosensitisers within the cells. 
Lastly, the presence of photosensitisers in cells and 
their fluorescence emission upon blue light (405 nm) 
excitation was observed using confocal fluorescence 
microscopy (Figure 2h-k). Here, while fluorescence 
emission of PPIX was readily observable, verteporfin 
fluorescence was very weak while Temoporfin fluo-
rescence was not detectable, despite photo-toxicity at 
this concentration.  
Owing to the high fluorescence yield and low Raman 
spectroscopic fluorescence background of PPIX 
(Figure 2i and Supplementary Figure 5), which offers 
the potential for tumour imaging and treatment moni-
toring in vivo, we investigated the use of clinically-
relevant Raman spectroscopy and PDT lasers through 
our multimodal fibreoptic probe with 5-ALA induced 
PPIX in vitro. LIVE/DEADTM assays of cells incu-
bated with 5-ALA indicated extensive, highly local-
ised cell death at the point of 633 nm laser applica-
tion whilst minimal cell death was observed for the 
785 nm laser and no illumination control cells despite 
785 exposure being 34 times greater than the maxi-
mum permissible skin exposure limit of 1.63 W.cm-2 
defined by the American National Standards Institute 
(Figure 3a-c)53,54. In the absence of 5-ALA induced 
PPIX, minimal cell death was observed for all three 
conditions (Figure 3d-f).  
 
Figure 3 | Compatibility of Raman Spectroscopy and Photodynamic Therapy Multimodal Fibreoptic Probe In Vitro. (a-
f) LIVE/DEADTM stain of A549 cells incubated with 5-ALA/PPIX and exposed to laser light at 100 mW for 120 seconds 
(total exposure 34 W.cm-2, maximum permissible skin exposure 1.5 W.cm-2) (scale bars 400 μm). (a) 5-ALA/PPIX, 633 
nm laser (multiple images manually stitched together), (b) 5-ALA/PPIX, 785 nm laser, (c) 5-ALA/PPIX, no illumination, (d) 
Control, 633 nm laser, (e) Control, 785 nm laser, (f) Control, no illumination. 
 
Taken together, the in vitro results presented here 
indicate a high level of compatibility between 785 
nm Raman spectroscopy and the three photosensitis-
ers examined. Of these photosensitisers, 5-ALA in-
duced PPIX demonstrated the lowest impact on Ra-
man spectra, ready fluorescence observation under 
blue light excitation, and has the widest range of 
clinical PDT approvals, making it a clear choice to 
take forward for in vivo investigations. 
In Vivo Cancer Theranostics 
To demonstrate the potential of our theranostic ap-
proach for cancer, we next conducted an in vivo 
study of SW1222 colorectal tumour xenografts in 
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nu/nu mice. Ten female nu/nu mice with SW1222 
tumours on their right flank following subcutaneous 
injection with 1x106 SW1222 cells, engineered to 
express the firefly luciferase gene for biolumines-
cence image (BLI), were split into a control group 
and a PDT group (N = 5 in each group). Raman spec-
tra were acquired (785 nm, 100 mW, 1 s) from the 
tumours and control flanks of both PDT mice and 
control mice prior to and 4 h post 5-ALA administra-
tion in PDT mice (Figure 4). Prominent Raman peaks 
were observed for both the tumour and control tissue 
at 936 cm-1 (ν(C–C) proteins), 1078 cm-1 (ν(C–C) of 
lipids), 1265 cm-1 (amide III ν(C–N) and δ(N–H) of 
proteins), 1302 cm-1 (CH2 twisting and wagging of 
lipids), 1445 cm-1 (δ(CH2) deformation of proteins 
and lipids), 1655 cm-1 (amide I ν(C=O) of proteins), 
in line with previous in vivo Raman spectroscopic 
studies27,28,55. Significant Raman spectral differences 
between the control and SW1222 tumour tissue were 
observed both before and after 5-ALA administra-
tion, with greater peak intensities in the control tissue 
as compared to the tumour tissue at 1265 cm-1, 1302 
cm-1, 1445 cm-1, and 1655 cm-1 (Figure 4c). Notably, 
we observed an up-regulation of protein content in 
tumour tissue, as indicated by an increase of the 1655 
cm-1 peak relative to the 1445 cm-1 peak as well as a 
slight broadening of the 1655 cm-1 peak relative to 
the control tissue, in line with previous Raman spec-
troscopic studies27,55. An increase in background 
fluorescence intensity was observed in the raw Ra-
man spectra 4 h post 5-ALA administration for both 
control and SW1222 tumour tissue (Supplementary 
Figure 8a). However, upon spectral processing much 
of these differences were accounted for such that 
visual discrimination of spectra taken prior to and 4h 
post 5-ALA administration was difficult (Figure 4c). 
PLS-DA of processed Raman spectra from control 
and SW1222 tissues (performed across control and 
SW1222 tumour tissue, irrespective of PPIX pres-
ence) demonstrated a cross-validation accuracy of 
97.4%, indicating the feasibility of highly accurate 
Raman diagnostics on PPIX-containing tissues (Fig-
ure 4d, Supplementary Figure 9), as indicated by 
previous studies56. Interestingly, despite being per-
formed across tissues irrespective of PPIX presence, 
the PLS-DA successfully separated tumour tissue 
pre-PPIX and 4 h post 5-ALA, while failing to per-
form the same separation for the control tissues. 
Analysis of the mean spectra and PLS-DA latent 
variables indicate the influence of the peak at 1550 
cm-1 in the separation of pre- post-PPIX tumour tis-
sue, with this peak notably having previously been 
attributed to porphyrins57. Confirmation of PPIX 
tumoural accumulation was performed for control 
SW1222 tumours and PDT SW1222 tumour tissues 
following re-administration of 5-ALA 6 days post 
PDT (Supplementary Figure 8b-c). 
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Figure 4 | Raman Spectral Diagnostics of PPIX Positive SW1222 Tumours In Vivo. (a) Integrated fibreoptic photody-
namic Raman theranostic system. (b) In vivo Raman spectral acquisitions from nude mouse. (c) Mean processed Raman 
spectra of control flanks and tumours in mice pre-5-ALA induced PPIX and 4 hours post-5-ALA injection (50 mg/kg) (n = 
18-20, N = 5). (d) Partial Least Squares – Discriminant Analysis of processed Raman spectra from control flanks and 
tumours performed across control and SW1222 tumour tissue irrespective of photosensitiser presence (n = 18-20, N = 
5).  
Lastly, we evaluated the remaining two steps of our 
proposed theranostic workflow (Figure 1b). At 4 h 
post 5-ALA administration, PDT mice were exposed 
to 633 nm laser light, applied through the same mul-
timodal fibreoptic probe used for Raman spectro-
scopic diagnosis, with a fluence rate of 50 mW/cm2 
and a total fluence of 30 J/cm2. Here, using a com-
paratively low PDT dose, we first examined whether 
PDT-mediated tumour control was possible follow-
ing Raman spectroscopic diagnosis of PPIX-
containing tissues and secondly, whether Raman 
spectroscopy could be used to perform post-treatment 
monitoring of the affected tissues. BLI imaging of 
control and PDT tumours prior to 5-ALA administra-
tion/PDT, at 3 days post-PDT, and at 6 days post-
PDT demonstrated a significant reduction in BLI 
signal, indicative of reduced tumour growth at 6 days 
post-PDT relative to control tumours (one outlier 
PDT tumour excluded as determined by the 1.5x 
interquartile range (IQR) test, 22.2% normalised 
tumour growth at 3 days) (Figure 5a-b). Importantly, 
these data demonstrate that significant photosensitis-
er photobleaching did not occur following Raman 
spectroscopic diagnosis of PPIX-containing tissues. 
While there was no statistically significant difference 
in excised tumour mass for either group, 53.4 ± 37.6 
mg for the control group vs. 52.8 ± 18.8 mg for the 
PDT group (mean ± STD, n = 5), BLI results did 
align well with post-treatment Raman spectroscopic 
molecular monitoring. Sequential Raman spectral 
analysis, performed via difference spectra between 
tumours and corresponding control tissue at each 
timepoint, initially indicated larger discrepancies for 
the PDT tumours than for the control tumours prior 
to PDT (day 0). However, at 3- and 6 days post-PDT 
the opposite was true, with PDT tumour discrepan-
cies decreasing, while control tumour discrepancies 
increased across the 1265 cm-1, 1302 cm-1, 1445 cm-1, 
and 1655 cm-1 peaks (Figure 5c). We hypothesise 
that these spectral changes observed in the PDT tu-
mours correspond to a small reduction in tumour load 
(i.e. the local density of tumour cells), resulting in a 
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lower proportion of tumour cells in the Raman sam-
pling volume. This thus suggests the feasibility of a 
Raman spectral method for post-treatment response 
monitoring at the molecular level and points to the 
potential of our single-device approach to diagnosis, 
treatment, and post-treatment monitoring.  
  
 
Figure 5 | BLI and Raman Monitoring of PDT Efficacy for SW1222 Tumours. (a) Exemplar BLI image used for assess-
ment of tumour size. (b) BLI-measured tumour growth for control (N = 5) and PDT (N = 4, 1 outlier excluded as deter-
mined by the 1.5x IQR test, 22.2% normalised tumour growth at 3 days) mice at 3- and 6-days post-PDT (normalised to 
BLI-measured tumour sizes prior to PDT) (data are shown as mean +/- STD) (two-tailed Welch’s t-test, * P < 0.05). (c) 
1440 cm-1 peak intensity difference for control and PDT mice calculated from the difference spectra shown in (d & e) at 
day 3 and day 6, normalised to day 0 (data are shown as mean +/- STD) (two-tailed Welch’s t-test, *** P < 0.005). (d) 
Mean Raman difference spectra between tumour tissue and control tissue for control (n = 20, N = 2) and PDT (n = 20, N 
= 5) mice before (day 0) and 3- and 6-days post-PDT. (e) Magnified view of difference spectra shown in (d) between 
1350-1550 cm-1. 
Discussion 
Theranostic approaches to cancer management offer 
the potential for patient- or tumour-tailored therapies 
based on real-time diagnostic feedback. Striving for 
this goal, theranostic systems have become increas-
ingly advanced, incorporating an array of diagnostic 
and therapeutic modalities such as CT, PET, MRI, 
and photoacoustic imaging, as well as laser ablation, 
and photo- and chemotherapies and into various 
theranostic nanoparticle constructs8,58–61. However, 
despite these developments in theranostic platforms, 
clinical translation continues to be stymied by on-
going concerns over the safety and efficacy of the 
nanoparticle constructs on which they rely18,62.  
The goal of this work was thus to develop an optical 
theranostic system that avoided the need for nanopar-
ticles altogether. To this end, we developed a 
theranostic approach through application of a fibre-
optic probe. Owing to the recent development of 
small, portable fibreoptic probes63–65, accurate, real-
time Raman spectroscopic cancer diagnosis in vivo is 
readily achievable.  By employing a custom-built 
fibreoptic probe, we combined Raman spectroscopic 
diagnosis with PDT for cancer theranostics. Crucial-
ly, this approach enables us to avoid many of the 
pitfalls of existing theranostic systems.  
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To investigate the clinical potential of this approach, 
we first detailed the complementarity of Raman spec-
troscopy and PDT. We showed that through careful 
material and parameter selections, Raman spectro-
scopic classification of photosensitiser-positive cells 
and tissues is feasible without inadvertent photosen-
sitiser activation or photobleaching. Through in vitro 
experimentation, we identified PPIX as a particularly 
strong candidate for nanoparticle-free theranostics in 
vivo. Lastly, we demonstrated our optical theranostic 
approach using the custom-built, fibreoptic probe for 
colorectal xenograft tumours in an in vivo mouse 
model. We demonstrated that, using this approach, 
we could effectively perform accurate diagnosis, 
enable tumoural control, and achieve post-treatment 
response monitoring at the molecular level. Together 
these data thus highlighted the potential of our 
theranostic platform as an alternative strategy to-
wards theranostic clinical translation. 
Our method offers four key advantages over existing 
theranostic platforms. Firstly, it is unaffected by the 
significant toxicity and regulatory concerns levelled 
at inorganic nanoparticles18,66. Secondly, Raman 
spectroscopic diagnosis in this case is independent of 
the tumoural accumulation of photosensitisers (or 
other nanoparticles), removing concerns about nano-
particle targeting or imaging contrast for diagnosis 
(though photosensitiser tumoural accumulation re-
mains essential for therapeutic purposes)67. Thirdly, 
the separation of diagnostic and therapeutic functions 
avoids trade-offs (e.g. circulation time, targeting, 
dosage) between modalities that hamper existing 
theranostic systems, limiting the efficacy of the indi-
vidual components3. Finally, our system avoids the 
need for the complex, lengthy, and costly synthesis 
processes often required for the production of multi-
functional theranostic nanoparticles, thereby reduc-
ing the associated costs and regulatory hurdles22.  
While our proposed theranostic system offers many 
advantages over existing theranostic platforms, it 
also faces several limitations. Firstly, as both Raman 
spectroscopy and PDT are light-based techniques, 
each is constrained by the penetration of light into 
tissue, making the system suitable only for surface 
lesions (i.e. early-stage cancers or pre-cancerous 
stages) or endoscopically-accessible lesions17,67. Sec-
ondly, while PDT has shown utility across many 
different cancers, treatment success is largely de-
pendent on sufficient and preferential uptake of a 
photosensitiser into diseased tissue17. While devel-
opment of increasingly powerful photosensitisers is 
ongoing, with a focus on increasing targeting effica-
cy and enabling combination therapies68–70, treatment 
efficacy can be limited relative to other modalities. 
Lastly, although the safety and efficacy of Raman 
spectroscopic diagnosis has been successfully 
demonstrated across thousands of patients and many 
different cancers, clinical approval currently only 
exists for skin cancer applications, with work ongo-
ing to realise Raman spectroscopic diagnosis for 
additional diseases30,71. 
In conclusion, we have developed a multimodal fi-
breoptic probe for nanoparticle-free cancer 
theranostics, combining Raman spectroscopic diag-
nostics with photodynamic therapy. We have suc-
cessfully demonstrated the utility of this system for 
the in vivo diagnosis, treatment, and post-treatment 
monitoring of cancerous lesions. Importantly, our 
system achieves this without the need for complex, 
costly, and potentially toxic nanoparticles. This thus 
represents an alternative theranostic cancer manage-
ment approach with improved clinical translation 
potential. 
 
Materials and Methods 
Fibreoptic Photodynamic Raman Theranostic 
Platform 
The photodynamic Raman theranostic platform com-
prises five key components; a custom-built multi-
modal fibreoptic probe (EmVision LLC), a spectro-
graph (OceanOptics Inc), a laser source for Raman 
spectroscopy (785 nm, 600 mW, B&W Tek), a laser 
source for photodynamic therapy (633 nm, 150 mW, 
Roithner Lasertechnik), and a computer (Lenovo 
Thinkpad  T460, Intel Core i5-6200U CPU) with 
custom-built software for system control. The probe 
tip uses a two-part lens to focus light from both the 
Raman spectroscopy and PDT lasers and is designed 
for close-proximity or direct contact Raman spectro-
scopic measurements (working distance: < 0.5 mm, 
785 nm tissue penetration depth: ~ 1 cm in skin, but 
tissue-dependent)72,73. Raman spectroscopic diagno-
sis followed by PDT is thereby performed using a 
single probe, with lasers controlled through clinician-
facing custom-built software. 
Photosensitiser Fluorescence Characterisation 
Photosensitiser fluorescence emission was character-
ised using a Horiba FL-1000 spectrofluorometer. For 
each photosensitiser (Protoporphyrin IX (PPIX) 
(Sigma-Aldrich), Verteporfin (Sigma-Aldrich), Te-
moporfin (Biolitec)), two fluorescence spectra were 
acquired with 1 nm step and 5 nm slit widths. Emis-
sion spectra between 450 nm and 785 nm were ac-
quired following excitation at 405 nm, while emis-
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sion spectra between 805 nm and 1000 nm were ac-
quired following excitation at 785 nm.  
10,000 ng/mL solutions of each photosensitiser were 
prepared in PBS from concentrated stock solutions. 
Five Raman spectra were collected from each solu-
tion using the custom-built multimodal fibreoptic 
Raman probe (EmVision) using a 785 nm Raman 
laser with 100 mW power output and 1 second inte-
gration time. Serial dilutions of each solution were 
thus prepared, and Raman spectra recorded with a 
Raman spectrum of PBS as a baseline. 
Cell Culture 
Cell experiments were performed using two human 
breast cancer cell lines (MDA-MB-231 and MDA-
MB-436) (ATCC) and one human lung cancer cell 
line (A549) (ATCC). Cell lines were authenticated 
using STR profiling. Briefly, MDA-MB-231 and 
MDA-MB-436 cells were grown at 37 ˚C and 5% 
CO2 in high glucose (4.5 g/L) DMEM GlutaMax 
(Life Technologies) supplemented with 10% (v/v) 
fetal bovine serum (FBS), 1x penicillin-streptomycin, 
1x non-essential amino acids, and 20 mM pH 7.3 
HEPES buffer solution. A549 cells were grown at 37 
˚C and 5% CO2 in RPMI 1640 (Life Technologies) 
supplemented with 10% (v/v) FBS, 1x penicillin-
streptomycin, 1x non-essential amino acids, and 20 
mM pH 7.3 HEPES buffer solution. SW1222 human 
colon rectal cancer cells (ATCC) used for in vivo 
experiments were grown at 37 ˚C and 5% CO2 in 
DMEM (Life Technologies), supplemented with 10% 
(v/v) FBS and 1x penicillin-streptomycin. 
Confocal Raman Spectroscopy 
0.1 x 106 cells were seeded onto 25 mm diameter 
MgF2 windows (Global Optics) in a 6-well plate and 
incubated for 24 hours. Cells were treated with the 
relevant photosensitiser in serum-free DMEM at the 
appropriate concentration and duration (1 hour, 100 
ng/mL for Verteporfin; 3 hours, 10 mM for 5-ALA; 
24 hours, 10 ng/mL for Temoporfin) and were then 
fixed with 4% paraformaldehyde (PFA) solution for 
20 minutes at room temperature and stored at 4 ˚C in 
PBS until required for imaging. Cell spectra were 
obtained from cells in PBS using a 63x water-
immersion objective lens and a 100 μm fibre acting 
as a confocal pinhole on a confocal Raman micros-
copy setup (Witec GmbH). Raman spectra were ob-
tained using a 785 nm laser (Toptica Extra) with a 
power of ~80 mW and a 10 second integration time. 
For each cell, 5 spectra were obtained from random 
locations within the cell. Spectral processing was 
performed in MATLAB (2017b) using scripts devel-
oped in-house. First, the spectra were cropped to 
remove laser contribution and the fluorescence back-
ground was removed using a Whittaker filter baseline 
subtraction (λ = 100,000). Cosmic ray peaks present 
in the spectra were removed and the spectra were 
smoothed using a 1st order Savitzky-Golay filter with 
a frame width of 7. Partial least squares-discriminant 
analysis (PLS-DA) was performed using PLS 
Toolbox (Eigenvector Research) within the 
MATLAB environment. Pre-processed, normalised 
(area under the curve), and mean-centred spectra 
were classified using PLS-DA performed with 6 
latent variables and a Venetian blinds cross-
validation with 10 data splits.  
Confocal Fluorescence Imaging 
0.3 x 106 A549 cells were seeded onto sterile glass 
coverslips in a 6-well plate in supplemented RPMI. 
24 hours post seeding, RPMI was removed from the 
cells and cells were washed with DPBS. Cells were 
then incubated at 37 ˚C and 5% CO2 in one of the 
following: serum-free DMEM for 1 hour; 100 ng/mL 
Verteporfin in serum-free DMEM for 1 hour; 10 mM 
5-ALA in serum-free DMEM for 3 hours; 10 ng/mL 
Temoporfin in serum-free DMEM for 24 hours. Fol-
lowing incubation, photosensitiser solutions were 
removed and cells washed with DPBS. Cells were 
then fixed with 4% (v/v) PFA solution for 20 minutes 
at room temperature. After fixation, PFA solution 
was removed and cells washed twice with DPBS. 
Cell staining (under dark conditions) was performed 
as follows. DPBS was removed from cells and cells 
were incubated with 0.2% Triton-X in DPBS for 10 
minutes at room temperature. Triton-X was removed 
from cells and cells washed three times with DPBS. 
Cells were then incubated with 5% (w/v) bovine 
serum albumin (BSA) (Sigma-Aldrich) for 1 hour at 
room temperature. BSA was removed from cells and 
cells washed twice with DPBS. Cells were then incu-
bated with AlexaFluor 488-conjugated Phalloidin 
(Thermo Fisher), 1:40 in DPBS for 45 minutes at 
room temperature. Solution was removed and cells 
were washed 5 times for 5 minutes each time with 
0.2% (v/v) Tween 20 (Sigma-Aldrich) in DPBS. 
Cells were then washed twice with DPBS. Coverslips 
were then removed from 6-well plate and mounted 
onto microscope slides (VWR) using Fluoromount 
(Serva) and allowed to dry before imaging. Imaging 
was performed using a Leica SP5 inverted confocal 
microscope equipped with a 405 nm diode laser and 
a 20x objective. Excitation was performed at 405 nm, 
with collection from 630 nm to 800 nm. 
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LED Array Construction and Characterisation 
Four single-colour LED arrays, consisting of 96 
LEDs in a 12 x 8 parallel-series arrangement, were 
constructed using LEDs with wavelengths corre-
sponding to photosensitiser activation or Raman im-
aging (631 nm - LED631E (ThorLabs), 660 nm - 
SSL-LX5093XRC/4 (Lumex), 690 nm - LED690-
03AU (Roithner LaserTechnik GmbH), 780 nm - 
LED780 (ThorLabs). LEDs were arranged on a cir-
cuit board (RS Components) such that each LED 
illuminated a single well of a 96-well plate. LEDs 
were soldered in place with a resistor for each row of 
8 LEDs to regulate the LED current loading. Optical 
power output was characterised using a PM100D 
optical power metre (ThorLabs), tuned to 633 nm, 
660 nm, 690 nm, or 785 nm with the LEDs tuned to 
approximately 5 mW/cm2 (3.5 mW/cm2 for 660 nm 
LEDs). 
Cell Viability Assay 
Using clear 96-well plates, cells were seeded at a 
concentration of 10,000 cells per well into the interi-
or wells of the plates (columns 3-11, rows B-G inclu-
sive) in 200 μL of serum-supplemented DMEM 
(MDA-MB-231 and MDA-MB-436 cells) or sup-
plemented RPMI (A549 cells). Outer wells were 
filled with 200 μL of supplemented DMEM (MDA-
MB-231 and MDA-MB-436 cells) or supplemented 
RPMI (A549 cells). Cells were incubated at 37 ˚C 
and 5% CO2 for 24 hours before photosensitiser ad-
ministration. After 24 hours of incubation, supple-
mented media (DMEM or RPMI) was replaced with 
photosensitiser-containing, serum-free DMEM at 
various concentrations and the plates incubated for 1 
hour (Verteporfin), 3 hours (5-ALA), or 24 hours 
(Temoporfin) under low light conditions at 37 ˚C and 
5% CO2. The photosensitiser solution was then re-
moved and cells were washed once with DPBS and 
serum-free DMEM was added to wells. Cells were 
then illuminated from below using LED arrays set to 
a power output of ~ 5 mW per LED for 15 minutes 
(Verteporfin) or 25 minutes (5-ALA and Temo-
porfin) (power output of 660 nm LEDs was limited 
to ~3.5 mW). 96-well plates were then incubated for 
24 hours at 37 ˚C and 5% CO2 under low-light condi-
tions. 24 hours post illumination, 10 μL of cell-
counting kit 8 (CCK-8) substrate (Sigma Aldrich) 
was added to each well and the plates incubated for 3 
hours at 37 ˚C and 5% CO2. After 3 hours, the ab-
sorbance of each well was measured at 450 nm using 
a plate reader (SpectraMax M5). 
LIVE/DEAD
TM
 Assay 
1 x 106 A549 cells were seeded into each of the wells 
of a 6-well plate in serum-supplemented RPMI and 
incubated for 24 hours at 37 ˚C and 5% CO2. Cells 
were then incubated with serum-free DMEM with or 
without 10 mM 5-ALA for 3 hours at 37 ˚C and 5% 
CO2. Solutions were then removed, and cells washed 
with DPBS. Serum-free DMEM was then added to 
all cells. Cells in each well were illuminated using 
the multimodal optical probe and associated lasers 
for Raman spectroscopy and PDT. The probe was 
placed underneath the centre of each well and held in 
place by a support stand. Laser outputs were adjusted 
to 100 mW and cells illuminated for 120 seconds 
with one of the lasers (no laser illumination for con-
trol cells) before the plate was returned to the incuba-
tor for 24 hours at 37 ˚C and 5% CO2. After 24 hours 
incubation, a LIVE/DEADTM assay was performed 
using a 2 μM calcein AM (Thermo Fisher Scientific) 
and a 4 μM ethidium homodimer-1 (Thermo Fisher 
Scientific) solution in DPBS. Media was removed 
from the cells and cells were washed with DPBS. 
LIVE/DEADTM reagent was added to the cells and 
incubated for 30 minutes at room temperature. Rea-
gent was removed from cells and cells washed with 
DPBS. Cells were then placed in DPBS for immedi-
ate imaging. Imaging was performed using an Olym-
pus IX71 inverted fluorescence microscope with a 4x 
objective. Multiple images were manually stitched 
together for Figure 3a. 
Ethics Statement 
All animal studies were approved by the University 
College London Biological Services Ethical Review 
Committee and licensed under the UK Home Office 
regulations and the Guidance for the Operation of 
Animals (Scientific Procedures) Act 1986 (Home 
Office, London, United Kingdom) and United King-
dom Coordinating Committee on Cancer Research 
Guidelines for the Welfare and Use of Animals in 
Cancer Research74. All in vivo experiments were 
performed under isoflurane anaesthesia (1.5% - 2.5% 
isoflurane in oxygen 1.5 L/min). 
In Vivo Raman-PDT Theranostics  
Ten female CD1 nu/nu mice (6-8 weeks old, 25-30g) 
were subcutaneously injected with 1x106 cells from a 
human colorectal carcinoma cell line, SW1222, on 
their right flank. These cells were previously engi-
neered in-house to express the luciferase gene for 
bioluminescence imaging (BLI)75. Mice were housed 
for 8 days to allow tumours to develop. Prior to 5-
ALA administration, each tumour was imaged using 
BLI and 20 Raman spectra were collected from the 
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tumour and the control flank for each mouse using 
the theranostic system described using the 785 nm 
laser with a 100 mW power output and 1 second 
integration time. Five mice received a 50 mg/kg tail 
vein injection of a 15 mg/mL 5-ALA solution while 
five control mice received no injection. At 1, 2, and 4 
hours post 5-ALA administration, tumours were im-
aged using BLI and Raman spectra were obtained 
from the tumour and the control flanks of all mice as 
described. After the final Raman spectral acquisi-
tions, mice were treated with the 633 nm PDT laser 
with a fluence rate of 50 mW/cm2 and a total fluence 
of 30 J/cm2. Mice were rehoused and monitored for 6 
days post PDT. At 1, 3, and 6 days post PDT, tu-
mours of control and PDT mice were reimaged using 
BLI, and Raman spectra were obtained from the tu-
mour and the control flanks of all mice as described. 
At 6 days post PDT, the 5 PDT mice were re-injected 
with 50 mg/kg of a 15 mg/mL 5-ALA solution to 
enable quantification of PPIX tumoural uptake, but 
no additional PDT was performed. All mice were 
subsequently sacrificed by cervical dislocation, in 
accordance with local regulations, and tumours ex-
cised for PPIX quantification. 
Bioluminescence Imaging 
BLI was performed using IVIS Lumina (Perki-
nElmer, USA). Animals were administered 200 μL 
D-luciferin (Promega) intraperitoneally at 75 mg/kg. 
2 or 3 mice were imaged simultaneously per acquisi-
tion. Mice were anaesthetised and sequential BLI 
images were acquired 5 minutes after luciferin injec-
tion using auto exposure time with 0.5 minutes delay 
between two consecutive acquisitions. A circular 
region of interest (ROI) was placed over the tumour 
on the first image and subsequently pasted over every 
new image acquired until all ROIs reach their maxi-
mum intensity. The total signal in the ROI was quan-
tified as total flux (photons/s) using Living Image 
software version 4.5 (PerkinElmer). Representative 
images were presented using radiance (p/sec/cm2/sr) 
as the colour scale utilising the same software. 
PPIX Tissue Quantification Assay 
SW1222 colorectal tumours for PPIX quantification 
were stored on ice under dark conditions prior to 
processing. Tumours were weighed before immer-
sion in 1 mL of SolvableTM (PerkinElmer) and vials 
placed into an ultrasound bath at 45 °C until the tis-
sue was dissolved (~ 4 hours). Three 50 μL aliquots 
were taken from each tumour solution and each di-
luted in 1mL of SolvableTM before being placed into 
the ultrasound bath for a further 15 minutes. For each 
tumour solution aliquot, 700 μL was placed into a 
plastic cuvette and the absorption spectrum between 
350-750 nm recorded following excitation at 400 nm 
using a Horiba FL-1000 spectrofluorometer. Fluores-
cence spectra were cropped to between 450-750 nm, 
the background fluorescence spectrum of pure Solv-
able was subtracted, and then the tissue autofluores-
cence background was subtracted using a Whittaker 
filter (λ = 10) before filtering with a Savitzky-Golay 
filter (1st order, frame length = 7). A standard curve 
was developed using control tumour tissue, pro-
cessed as above, with increasing known amount of 
PPIX in a Solvable solution added to the cuvette. 
Standard curve fluorescence spectra were processed 
as described above. 
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Supplementary Information 
 
Supplementary Figure 1 | Photosensitisers for Raman-PDT Theranostics. (a-c) Chemical structures of clinically employed 
photosensitisers investigate for Raman-PDT theranostic system; (a) Protoporphyrin IX (PPIX), (b) Verteporfin, (c) Temo-
porfin. (d-f) Normalised fluorescence emission spectra (ex 405 nm) of (d) PPIX, (e) Verteporfin, (f) Temoporfin. (g-i) Nor-
malised fluorescence emission spectra (ex 785 nm) of (g) PPIX, (h) Verteporfin, (i) Temoporfin. 
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Supplementary Figure 2 | Raw Raman Spectra of Photosensitiser Solutions. (a-c) Raw Raman spectra of (a) PPIX, (b) Te-
moporfin, and (c) Verteporfin serial dilutions as compared to PBS (n = 5). Major peaks seen in (b) and (c) correspond to 
background traces of solvents used in preparation of Temoporfin and Verteporfin solutions. (d) Peak fluorescence back-
grounds for photosensitizer serial dilutions (mean ± S.D., n = 5). 
 
 
Supplementary Figure 3 | Photosensitiser Cell Viability Assays. (a-c) Cell viability assays of MDA-MB-231 cells incubated 
with (a) 5-ALA, (b) Temoporfin, (c) Verteporfin. (d-f) Cell viability assays of MDA-MB-436 cells incubated with (d) 5-ALA, 
(e) Temoporfin, (f) Verteporfin. (mean ± S.D., N = 3, n = 6) (Error bars: mean ± STD) (Multiple comparisons t-test, Bonfer-
roni post hoc correction, * P < 0.05, ** P < 0.01, *** P < 0.001). 
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Supplementary Figure 4 | Raman Difference Spectra of Photosensitiser Cells. (a-c) Raman difference spectra (10 s inte-
gration time) of cells in the presence of different photosensitisers (phenol red-free DMEM (Control), 5-ALA (10000 µM), 
Verteporfin (100 ng/mL), or Temoporfin (10 ng/mL)), calculated as ‘PS Cell – Control Cell’ for (a) A549 cells, (b) MDA-MB-
231 cells, and (c) MDA-MB-436 cells (N = 10, n = 5). 
 
 
Supplementary Figure 5 | Raw Raman Spectra of Photosensitiser Cells. (a-c) Raw Raman spectral acquisitions (10 s inte-
gration time) of (a) A549 cells, (b) MDA-MB-231 cells, and (c) MDA-MB-436 cells in the presence of different photosensi-
tisers (phenol red-free DMEM (Control), 5-ALA (10000 µM), Verteporfin (100 ng/mL), or Temoporfin (10 ng/mL)) (N = 10, 
n = 5). 
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Supplementary Figure 6 | Mean Spectral Coefficient of Variation and Signal-to-Noise Ratio of Photosensitiser Cells. (a-b) 
Mean spectral coefficient of variation of (a) raw and (b) processed Raman photosensitiser cell spectra. (c-d) Mean SNR of 
(c) raw and (d) processed Raman photosensitiser cell spectra (N = 10, n = 5) (Error bars: mean ± STD) (Two-way analysis 
of variance (ANOVA), Tukey’s honest significant differences (HSD) post hoc correction, * P < 0.05, ** P < 0.01, *** P < 
0.001). 
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Supplementary Figure 7 | Photosensitiser Cell Raman Spectra PLS-DA. (a-i) Matrix plot of (a, e, i) latent variables 1-3 for 
PLS-DA of processed Raman spectra performed across the three cell lines, A549, MDA-MB-231, and MDA-MB-436 (blind 
to the presence or absence of different photosensitisers) (N = 40, n = 5). (j-l) PLS-DA latent variables 4-6. Percentages 
indicate percentage variance explained by each latent variable. 
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Supplementary Figure 8 | Confirmation of PPIX Uptake SW1222 Tumours In Vivo. (a) Mean raw Raman spectra of control 
flanks and tumours in mice pre-5-ALA induced PPIX and 4 hours post-5-ALA injection (50 mg/kg) (n = 18-20, N = 5). (b) 
Emission spectra of control tumours and PPIX positive tumours following re-administration of 5-ALA (50 mg/kg) with a 4-
hour incubation time 6 days post PDT treatment immediately prior to tumour excision. (c) Quantification of PPIX tumour 
concentration for control and PPIX positive tumours. 
 
 
Supplementary Figure 9 | PPIX+ SW1222 Tumours Raman Spectra PLS-DA. (a-i) Matrix plot of (a, e, i) latent variables 1-3 
for PLS-DA of processed Raman spectra for control tissue and tumour tissue pre-5-ALA induced PPIX and 4h post 5-ALA 
injection (50 mg/kg) (n = 18-20, N = 5). Percentages indicate percentage variance explained by each latent variable. 
 
 
               
 
     
     
     
     
     
                       
 
  
 
  
 
 
 
 
 
 
  
  
 
 
  
 
  
  
                   
              
            
               
 
     
     
     
     
               
 
  
 
  
 
 
 
 
 
 
  
  
 
 
  
 
  
  
                 
               
               
               
               
             
             
             
             
             
                  
    
    
    
                  
  
  
 
 
  
 
  
  
  
                  
                 
                       
                      
   
                           
      
      
     
     
     
                      
 
 
 
  
 
 
 
 
 
 
  
 
  
 
 
 
                  
                                       
                       
                           
      
      
     
     
     
                      
 
 
 
  
 
 
 
 
 
 
  
  
 
 
 
                  
                                       
                       
                           
      
      
     
     
     
                      
 
 
 
  
 
 
 
 
 
 
  
 
  
 
 
 
                  
                                       
                      
                           
      
      
     
     
     
                      
 
 
 
  
 
 
 
 
 
 
  
  
 
 
 
                  
                                       
                      
                           
      
      
     
     
     
                     
 
 
 
  
 
 
 
 
 
 
  
 
  
 
 
 
                  
                                       
                      
                           
      
      
     
     
     
                     
 
 
 
  
 
 
 
 
 
 
  
 
  
 
 
 
                  
                                       
                       
                  
    
    
    
   
   
                  
 
 
  
 
  
  
 
  
  
 
 
  
 
  
  
  
                  
     
     
     
    
    
    
    
                  
 
 
  
 
  
  
 
  
  
 
 
  
 
  
  
  
                  
     
     
    
    
    
    
                  
 
 
  
 
  
  
 
  
  
 
 
  
 
  
  
  
      
      
     
   
   
   
